Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.

Paz Polak, VP of Computational Biology, C2i Genomics, recently posted on LinkedIn:

“In a correspondence letter we wrote for the New England Journal of Medicine (NEJM), we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures for example by whole-genome sequencing, could help understand why some endometrial patients with mismatch repair proficiency respond to immunotherapies. I advocate that every patient with an aggressive endometrial tumor should have whole-genome sequencing. This can guide treatments, whether it’s immunotherapies, PARP inhibitors, or other therapies.”

Source: Paz Polak/LinkedIn